FYB Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetFormycon’s low leverage and sizable equity base provide durable financial flexibility to fund R&D cycles and absorb setbacks common in biosimilar development. A stronger balance sheet reduces short-term refinancing risk and preserves strategic optionality for partnering or opportunistic investments over the next 2–6 months.
Improved Operating Cash FlowThe shift to positive operating cash flow in 2025 signals improving operational cash generation, which is a durable step toward self-funding development activities. If sustained, this reduces reliance on external financing for near-term programs and strengthens the company’s ability to execute clinical/regulatory milestones.
Partner-driven Commercial ModelFormycon’s partner-centric business model aligns development costs with commercialization expertise, limiting the need for a large in-house salesforce. This structure preserves capital, leverages partner market access, and allows Formycon to scale by securing milestone and royalty streams tied to successful approvals and launches.
Bears Say
Recent Revenue ContractionTwo consecutive years of revenue decline reduce milestone cadence and weaken recurring royalty visibility. Persistent top-line shrinkage undermines bargaining power with partners, constrains reinvestment capacity, and raises execution risk for ongoing programs if the trend continues over the next several quarters.
Deep Negative Free Cash FlowWorsening free cash flow despite positive operating inflows indicates heavy investment or funding gaps that aren’t covered by operations. Persistently negative FCF creates a medium-term funding risk that could force dilutive raises, more partner concessions, or increased debt, limiting strategic flexibility.
Profitability Volatility And Recent LossesLarge swings from profitability to substantial losses reflect execution and revenue timing risk inherent to biopharma milestones. This earnings volatility complicates planning, may reduce partner confidence in milestone delivery, and increases the likelihood of financing needs during loss-making periods.
Formycon AG News
FYB FAQ
What was Formycon AG’s price range in the past 12 months?
Currently, no data Available
What is Formycon AG’s market cap?
Formycon AG’s market cap is CHF311.83M.
When is Formycon AG’s upcoming earnings report date?
Formycon AG’s upcoming earnings report date is Aug 12, 2026 which is in 12 days.
How were Formycon AG’s earnings last quarter?
Currently, no data Available
Is Formycon AG overvalued?
According to Wall Street analysts Formycon AG’s price is currently Undervalued.
Does Formycon AG pay dividends?
Formycon AG does not currently pay dividends.
What is Formycon AG’s EPS estimate?
Formycon AG’s EPS estimate is -0.13.
How many shares outstanding does Formycon AG have?
Formycon AG has 17,672,928 shares outstanding.
What happened to Formycon AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Formycon AG?
Currently, no hedge funds are holding shares in CH:FYB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Formycon AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.17%
Trailing 12-Months
Company Description
Formycon AG
Headquartered in Planegg, Germany, Formycon AG, founded in 1999 and formerly known as Nanohale AG until 2012, specializes in the development and commercialization of biosimilar medications. Its robust product pipeline includes FYB201, a biosimilar equivalent to Lucentis, which is intended for the treatment of neovascular age-related macular degeneration and other severe eye conditions. The company is also progressing with FYB202, a biosimilar of Stelara, currently undergoing Phase III clinical trials for various inflammatory diseases, including moderate to severe psoriasis, Crohn's disease, and ulcerative colitis. Additionally, FYB203, a biosimilar candidate for Eylea, is in Phase III clinical trials, aiming to address similar ocular diseases like neovascular age-related macular degeneration. Further endeavors include the development of FYB206 and FYB207, with the latter being an antiviral treatment for COVID-19. To ensure the stability of its numerous drug candidates, Formycon AG maintains a collaborative agreement with Leukocare AG.
FYB Stock 12 Month Forecast
Average Price Target
―B.R.A.I.N. Biotechnology Research and Information Network
―
co.don AG
―
Medigene
―
Heidelberg Pharma AG
―
MagForce AG
―